Abstract:Introduction: Deep vein thrombosis (DVT) is a medical condition characterized by forming a blood clot, or thrombus, in one of the deep veins, typically in the legs. It is a type of venous thromboembolism, which refers to the formation of blood clots in the veins. It is caused by Virchow's triad (stasis, hypercoagulation, and endothelial injury). Objective: Our main objective is to explore the effectiveness and safety of rivaroxaban and edoxaban in treating lower extremity DVT. Methods: We conducted a retrospective study involving 406 patients subjected to DVT treatment using direct oral anticoagulants (edoxaban and rivaroxaban) at our hospital. We recruited adult patients (aged 18 years and more) diagnosed with lower extremity DVT and received treatment with either rivaroxaban or edoxaban as the primary anticoagulant therapy for DVT. We excluded patients who received treatment with other anticoagulant medications (warfarin and heparin) as the primary therapy for DVT. Results: The groups showed statistically significant differences in red blood cell count and hemoglobin levels, with the edoxaban group having high values. However, the 2 groups observed no statistically significant differences in creatinine clearance, white blood cell count, platelet count, C-reactive protein, and D-dimer levels. The difference in the incidence of pulmonary embolism between the 2 groups was statistically significant (P value < 0.001). The edoxaban group had fewer pulmonary embolism patients than the rivaroxaban group. The reduction in recurrent thrombosis was significantly higher in the rivaroxaban group compared to the edoxaban group. There were no significant differences in the major bleeding at various sites across the 2 treatment groups (P > 0.05). Conclusions: Rivaroxaban's pharmacokinetic profile includes rapid absorption and a relatively short half-life. It means that once administered, rivaroxaban quickly reaches its peak concentration in the blood and is subsequently eliminated from the body within a relatively short period. Edoxaban's pharmacokinetic profile may include slower absorption and a longer half-life than rivaroxaban. It can result in a slower rate of achieving peak concentration and a more prolonged presence in the bloodstream. These results emphasize the need for careful consideration of anticoagulant therapy in patients with underlying cancer and underscore the importance of managing risks while providing adequate anticoagulation to prevent thrombotic events.

Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban

Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban

[Anticoagulation therapy during pulmonary embolism follow-up in clinical practice]

Meta-analysis of Efficacy and Safety of Rivaroxaban for Treatment of Deep Venous Thrombosis

Direct Oral Anticoagulants for Pulmonary Embolism

Comparison of Rivaroxaban Mono-Therapy and Standard-Therapy Adjusted by CYP2C9 and VKORC1 Genotypes in Symptomatic Pulmonary Embolism.

Novel Challenges and Therapeutic Options for Pulmonary Embolism and Deep Vein Thrombosis

Endovascular treatments of acute pulmonary embolism in the post-fibrinolytic era: an up-to-date review

Venous Thromboembolism in Children: The Rivaroxaban Experience

Cutting-Edge Techniques and Drugs for the Treatment of Pulmonary Embolism: Current Knowledge and Future Perspectives

Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study

Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants

Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline

Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients with Acute Pulmonary Embolism.

Oral anticoagulation in patients with left ventricular thrombus: a systematic review and network meta-analysis with reconstructed time-to-event data

Rivaroxaban versus Vitamin K Antagonists (warfarin) based on the triple therapy for left ventricular thrombus after ST-Elevation myocardial infarction

Pharmacological Thromboprophylaxis for VTE Post-Endovenous Ablation of Varicose Veins: Network Meta-Analysis

The Effectiveness and Safety of Rivaroxaban and Edoxaban in the Treatment of Lower Extremity Deep Vein Thrombosis

NONANTICOAGULANT INTERVENTIONS IN VENOUS THROMBOEMBOLISM Thrombolytic therapy in acute venous thromboembolism

Anticoagulants for the treatment of isolated lower limb superficial vein thrombosis a Bayesian network meta-analysis of randomized controlled trials

Therapeutic or Prophylactic Anticoagulation in Acute Isolated Distal Deep Vein Thrombosis: Protocol for a Prospective, Multicentre, Single-Blind, Randomised Controlled Trial (TOP-IDDVT)